Floatz logo

Stx-0712

Acute Monocytic Leukemia

Solu Therapeutics, IncPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

14 Active assets in the Acute Monocytic Leukemia cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
Stanford University
Phase 3BBB
Cytosin-Arabinosid
Chinese PLA General Hospital
Phase 3BBB
Daunorubicin
National Cancer Institute (NCI)
Phase 3BBB
2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)-
National Cancer Institute (NCI)
Phase 2BBB
Cyclophosphamide
ECOG-ACRIN Cancer Research Group
Phase 3BBB

View all 50 →

Same molecule, other indications

Stx-0712 is also rated in:

therapy related acute myeloid leukemia and myelodysplastic syndromeDormant
CC
Indicative ·
41 / 100
View asset →
chronic myelomonocytic leukemiaDormant
C
Indicative ·
39 / 100
View asset →
acute myeloid leukemiaDormant
C
Indicative ·
36 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →